Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma

Saudi Medical Journal

Volumn 27, Issue 3, 2006, Pages 317-322

  Gedik, Gonca K ^a   Kiratli, Pinar O ^a   Tascioglu, Beliz ^a   Aras, Tulin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BONE SCINTISCANNING; BREAST CARCINOMA; CHEMOLUMINESCENCE; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC VALUE; ELECTROCHEMICAL DETECTION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROBABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC);

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33644977299     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Arslan N, Serdar M, Deveci S, Öztürk B, Narin Y, Iligan S et al. Use of CA 15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. Ann Nucl Med 2000; 14: 395-399.
2. Yildiz M, Oral B, Bozkurt M, Çobaner A. Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Ann Nucl Med 2004; 18: 501-504.
3. Buffaz PD, Gauchez AS, Caravel JP, Vuillez JP, Cura C, Agnuis-Delord C et al. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nucl Med 1999; 26: 8-11.
4. Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer 1999; 79: 1443-1447.
5. Boxer DI, Todd CEC, Coleman R, Fogelman I. Bone secondaries in breast cancer: the solitary metastases. J Nucl Med 1989; 30: 1318-1320.
6. Yasasever V, Dinçer M, Çamlica H, Karaloglu D, Dalay N. Utility of CA 15-3 and CEA in Monitoring Breast Cancer Patients With Bone Metastases: Special Emphasis on Spiking Phenomena. Clin Biochem 1997; 30: 53-56.
7. Willimas PL, Bannister LH, Berry MM, Collins P, Dyson M, Dussek SE, et al. Preoperative CA 15-3 Concentrations Predict Outcome of Patients with Breast Carcinoma. Cancer 1998; 83: 2521-2527.
8. Williams PL, Bannister LH, Berry MM, Collins P, Dyson M, Dussek JE, et al, editors. Gray's Anatomy. New York: Churchill Livingstone; 1995. p. 432-433.
9. Newton TH, Potts DG. Fetal Skull. In: Radiology of the skull and brain. The skull. Saint Louis: Mosby Company; 1971. p. 99-100.
10. Safi F, Kohler I, Röttinger E, Beger HG. The Value of the tumor Marker CA 15-3 in Diagnosis and Monitoring Breast Cancer. Cancer 1991; 68: 574-582.
11. Clinical Practice Guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843-2877.
12. Pons-Anicet DMF, Krebs BP, Namer MM. Value of CA 15-3 in the follow up of breast cancer patients. Br J Cancer 1987; 55: 567-569.
13. Crippa F, Bombardieri E, Seregni M, Castellani MR, Gasparini M, Maffioli L et al. Single determination of CA 15-3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med 1992; 36: 52-55.
14. Podoloff DA. Malignanat Bone Disease. In: Henkin RE, Boles MA, Karesh SM, Wagner RH, Dillehay GL, Halama JR, editors. Nuclear Medicine. St Louis (MO): Mosby; 1996. p. 1208-1222.
15. Lumachi F, Basso SFF, Brandes AA, Pagano D, Ermani M. Relationship Between Tumor Markers CEA and CA 15-3, TNM Staging, Estrogen Receptor Rate and MIB-1 Index in Patients with pT1-2 Breast Cancer. Anticancer Res 2004; 24: 3221-3224.